logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report
      • Health Canada Priority Review & Project Orbis Sub-Report
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report
      • Health Canada Priority Review & Project Orbis Sub-Report
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

New INESSS Evaluation Fee Schedule

June 2, 2021
-
Market Access News, Publications
-
Posted by Patrick Manfred - 2 min read.

Author: Patrick Manfred, Vice-President, TACT Conseil, Quebec Market Access Expert

 

Date: June 2, 2021

 

A proposal to modify the current regulation framing the fees payable to the Institut national d’excellence en santé (INESSS) to complete a scientific evaluation of a drug and/or a stable blood product was published in Part 2 of the Quebec Official Gazette, on March 18, 2021. If the Quebec government does not deviate from the regulatory calendar, the new fees are anticipated come into force as early as mid-June 2021. INESSS will update its fee schedule online as soon as the amendment to the Regulation respecting the fees payable by INESSS for the evaluation of a drug and a stable blood product is adopted. All the details related to INESSS submission fees can be found at:

https://www.inesss.qc.ca/en/themes/medicaments/manufacturer-information-centre/fees.html

Please find below the newly proposed fee schedule. Note, several new categories have been introduced. In addition, certain existing categories will experience a significant increase, while others (for example biosimilars) will only see a modest increase. 

 

FEES PAYABLE FOR THE VARIOUS SCIENTIFIC EVALUATIONS

 

Scientific evaluation Fees
Evaluation object Type
New cellular or gene therapy First evaluation $89,796 per indication
Re-evaluation $59,864 per indication
New medication with companion test or new indication of a listed medication with a companion test First evaluation $68,844 per indication
Re-evaluation $35,918 per indication
New drug or new indication for a currently listed drug or a stable blood product First evaluation $59,864 per indication
Re-evaluation $35,918 per indication
New cutting-edge therapeutic product First evaluation $89,796 per indication
New radiopharmaceutical First evaluation $89,796 per indication
Re-evaluation $35,918 per indication
New medical device directly linked to the administration of a drug First evaluation $59,874 per dossier
Re-evaluation $35,918 per dossier
New biosimilar First evaluation $8,980 per dossier
Subsequent evaluation (new indication) $8,980 per dossier
Re-evaluation $4,490 per dossier
New concentration, strength(s) or new form(s) of a currently listed drug First evaluation $8,980 per dossier
Re-evaluation $4,490 per dossier
New nutritional formula or combination of drugs already listed or a new diagnostic agent of a currently listed non-proprietary name already registered on the drug lists First evaluation $5,986 per dossier
Re-evaluation file $2,983 per dossier
New dressing First evaluation $11,973 per dossier
Re-evaluation $5,986 per dossier
Exemption from the application of the lowest price All exemption requests $8,980 per dossier

 

Reference

 

http://www2.publicationsduquebec.gouv.qc.ca/dynamicSearch/telecharge.php?type=13&file=2111A-F.PDF

 

Please contact Patrick Manfred for further information on this matter.

 

To receive timely industry updates and insights please be sure to sign up for Market Access Signals, our free e-mail newsletter service.

 

Share
Tags
Biosimilars
Blood Products
Cellular Therapy
Cost Recovery
Gene Therapy
Health Technology Assessment
HTA
INESSS
Market Access
Public Payers
Quebec
Radiopharmaceutical
Scientific Evaluation
Submission Fees
TACT
← PREVIOUS POST
Files Under pCPA Consideration for Greater Than 6 Months is the Highest its Been in a Year
NEXT POST →
Files Under pCPA Consideration for Greater Than 6 Months Drops Significantly

Patrick Manfred

Passionate about government relations, Patrick has acquired extensive expertise in analyzing health sector issues and developing particularly effective strategic plans to meet client needs while considering the impact on government decision-makers. Results-oriented, he is recognized for his ability to develop innovative solutions, with a win-win approach for the partners involved.
For over 15 years, he held senior positions across Canada, in business development, public and government relations, in various innovative companies. His knowledge and know-how affect both primary and specialized care, with demonstrated skills in negotiating and establishing rapid and optimal reimbursement of drugs and services in the public and private sectors, both in Quebec and in the rest of the country. Canada.

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
New INESSS Evaluation Fee Schedule